Meeting
2022 ASCO Annual Meeting
Defining transcriptomic profiles of early-stage mucinous breast cancers: A FLEX sub study.
Authors
Abirami Sivapiragasam
SUNY Upstate Medical University, Syracuse, NY
Abirami Sivapiragasam , Ryan Christopher Denley , Adam Brufsky , Esther Hoogland Rehmus , Joyce O'Shaughnessy , Jennifer A. Crozier , Sami Diab , Julie Barone , Jill Yeager , Priya Menon , Midas M. Kuilman , Lavanya Samraj , Lisa Eileen Blumencranz , M. William Audeh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Clinical Trial Registration Number
NCT03053193
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3134)
DOI
10.1200/JCO.2022.40.16_suppl.3134
Abstract #
3134
Poster Bd #
126
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Whole transcriptome analysis of tumors with discordant oncotype and MammaPrint results in the FLEX trial.
First Author: Matei P. Socoteanu
Poster
2022 ASCO Annual Meeting
Identification of transcriptional changes with MammaPrint and BluePrint in early-stage breast cancer after neoadjuvant chemotherapy.
First Author: Alice P. Chung
Poster
2021 ASCO Annual Meeting
Gene expression associated with lymphovascular invasion and genomic risk in early-stage breast cancer.
First Author: Nina D'Abreo
Poster
2023 ASCO Annual Meeting
FLEX, a real-world evidence full transcriptome study of 30,000 patients with early-stage breast cancer.
First Author: Eric Allen Brown